Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.

Sheila M. Rothman, Victoria H. Raveis, Anne Friedman, David J. Rothman

Research output: Contribution to journalArticle

Abstract

Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed. We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns. Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor. No HAO disclosed the exact amount of a Lilly grant. As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators, and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.

Original languageEnglish (US)
Pages (from-to)602-609
Number of pages8
JournalAmerican journal of public health
Volume101
Issue number4
DOIs
StatePublished - Apr 2011

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.'. Together they form a unique fingerprint.

  • Cite this